Clinical trial · Observational
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sarcopenic obesity occurs when there is a loss of muscle and gain of fat in the body. With this study, the investigators will explore how nutritional status at the beginning of the treatment can cause changes in your child's body fat compared to muscle in the body. The investigators will also look at how these changes can impact a child's cancer treatment, survival from treatment, and if there is any deterioration in health and nutrition status. The primary objective of this study is to establish the incidence of sarcopenic obesity, measured by dual-energy x-ray absorptiometry (DEXA), among Indian children and adolescents with acute lymphoblastic leukemia (ALL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcopenic Obesity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vegetarian Diet | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Vegetarian Diet
- description
- Includes children following a vegetarian diet.
- interventionNames
- Other: Vegetarian Diet
- label
- Non-Vegetarian Diet
- description
- Includes children following a non-vegetarian diet.
Primary outcomes (1)
- measure
- Incidence of Sarcopenic Obesity
- timeFrame
- 6 months
- description
- Incidence of sarcopenic obesity, measured by dual-energy x-ray absorptiometry (DEXA), among Indian children and adolescents with ALL.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed with ALL * Able to consume ≥ 80% of dietary requirements enterally * Adequate performance status (Lansky score ≥70) * Receiving standard treatment for ALL on or as per the Indian Childhood Collaborative Leukemia Group's protocol (ICiCLe). Exclusion Criteria: * Refusal of consent * Relapsed ALL * Down's syndrome; (Other congenital anomalies too) * Therapy initiated elsewhere
References
Publications (0)
Data not yet available